Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids
Y. Han, L. Yang, X. Duan, F. Duan, B. E. Nilsson-Payant, T. M. Yaron, P. Wang, X. Tang, T. Zhang, Z. Zhao, Y. Bram, D. Redmond, S. Houghton, D. Nguyen, D. Xu, , S. Chen
This study uses hPSC-derived lung organoids to identify FDA-approved drugs that inhibit SARS-CoV-2 entry and reduce infection in a model of human COVID-19.
bioRxiv · May 5, 2020 · PreprintMicrobiology